Novartis opens California site for RLT manufacturing
Novartis has opened a 10,000ft² radioligand therapy (RLT) manufacturing facility in Carlsbad in the US state of California, as part…
10 Nov 2025
Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal
Eli Lilly has agreed to a $475m licensing deal with MeiraGTx, marking the second eye disease gene therapy bet by the drugmaker in as many months. Eli Lilly will…
10 Nov 2025
CPHI 2025: directing AI-driven innovation to harness Europe’s data edge
Europe’s biopharma stakeholders should seek innovation through AI to meet the challenges of treatment resistance, drug affordability, and a creeping patent cliff, channelling the continent’s health data to catch up…
10 Nov 2025
Harbour BioMed and Evinova collaborate on AI biologics
Harbour BioMed and Evinova China have formed a collaboration to implement AI and digital technologies to improve biologics development. The partnership intends to enhance the efficiency of AI-enabled drug development…
10 Nov 2025
Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war…
10 Nov 2025
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer
Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in the US from Biofrontera and Ferrer Internacional. The topical cream is indicated to treat…
10 Nov 2025
SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases
SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA interference] candidates for metabolic diseases. These candidates will be developed using SanegeneBio’s…